SCHEMBL4172596

SCHEMBL4172596

CSc1nnc(-c2ccc(I)cc2)n1C

nearest known ligand 0.70

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.70
KDM4E B2RXH2 5/20 0.54
HPGD P15428 3/20 0.54
HSD17B10 Q99714 2/20 0.54
NPC1 O15118 5/20 0.50
KMT2A Q03164 4/20 0.46
MEN1 O00255 3/20 0.46
RAB9A P51151 3/20 0.46
CYP2C19 P33261 2/20 0.46
MAPT P10636 1/20 0.46
RGS12 O14924 1/20 0.46
CYP1A2 P05177 2/20 0.45
GLA P06280 1/20 0.45
GAA P10253 1/20 0.45
HTT P42858 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
CYP2C9 P11712 1/20 0.44
DRD2 P14416 1/20 0.44
HSD11B1 P28845 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1544564 0.82 ALDH1A1 (0.70) ALDH1A1KDM4EHPGDHSD17B10NPC1
SCHEMBL10916439 0.82 ALDH1A1 (1.00) ALDH1A1KDM4EHPGDHSD17B10NPC1
SCHEMBL974759 0.81 ALDH1A1 (0.69) ALDH1A1KDM4EHPGDHSD17B10NPC1
SCHEMBL1544895 0.80 ALDH1A1 (0.67) ALDH1A1KDM4EHPGDHSD17B10KMT2A
SCHEMBL10915111 0.79 ALDH1A1 (0.66) ALDH1A1KDM4EHPGDHSD17B10NPC1
SCHEMBL4184528 0.74 HSD11B1 (0.43) ALDH1A1HPGDNPC1KMT2AMEN1
SCHEMBL2004713 0.74 ALDH1A1 (0.59) ALDH1A1KDM4EHPGDHSD17B10NPC1
SCHEMBL8262279 0.73 ALDH1A1 (0.58) ALDH1A1KDM4EHPGDHSD17B10NPC1
SCHEMBL9223454 0.73 ALDH1A1 (0.62) ALDH1A1KDM4EHPGDHSD17B10KMT2A
SCHEMBL1545282 0.71 ALDH1A1 (0.56) ALDH1A1KDM4EHPGDHSD17B10NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090111857-A1 1,2,4-TRIAZOLE ETHER DERIVATIVES AS MODULATORS OF MGLUR5 ASTRAZENECA AB (SE) 2009-04-30 US claimed
WO-2009054785-A1 1,2,4-TRIAZOLE ETHER DERIVATIVES AS MODULATORS OF MGLUR5 ASTRAZENECA AB (SE) 2009-04-30 WO claimed
US-20090111857-A1 1,2,4-TRIAZOLE ETHER DERIVATIVES AS MODULATORS OF MGLUR5 ASTRAZENECA AB (SE) 2009-04-30 US disclosed
US-20090111857-A1 1,2,4-TRIAZOLE ETHER DERIVATIVES AS MODULATORS OF MGLUR5 ASTRAZENECA AB (SE) 2009-04-30 US disclosed
US-20090111857-A1 1,2,4-TRIAZOLE ETHER DERIVATIVES AS MODULATORS OF MGLUR5 ASTRAZENECA AB (SE) 2009-04-30 US disclosed
WO-2009054785-A1 1,2,4-TRIAZOLE ETHER DERIVATIVES AS MODULATORS OF MGLUR5 ASTRAZENECA AB (SE) 2009-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090111857-A1 1,2,4-TRIAZOLE ETHER DERIVATIVES AS MODULATORS OF MGLUR5 GRM5, GRIK5, GRM1 ALDH1A1 4175/4885KDM4E 916/4885HPGD 2910/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.